Stoke Therapeutics’ Dravet syndrome drug has been freed from a partial hold, clearing the way for the construction of a phase 3 program.

Novo Nordisk has axed its once-monthly dual GLP-1/GIP receptor agonist, ending (PDF) development of a drug candidate that it singled out as an exciting part of its pipeline earlier this year.

Exelixis is giving up on its tissue factor (TF)-targeting antibody-drug conjugate after concluding the candidate was unlikely to best Pfizer and Genmab’s Tivdak.

Neuralink has implanted its device in a second patient, according to the startup’s owner Elon Musk.

After BioMarin conducted a spring clean of its pipeline in April, the company has decided that it also needs to offload a preclinical gene therapy for a condition that causes heart muscles to thicken.

A new global life science credit firm, dubbed Symbiotic Capital, has raised more than $600 million.

Ultimovacs’ cancer vaccine UV1 has failed yet another midphase clinical trial. The third flop, this time in head and neck cancer, leaves UV1 with one shot at salvation before the Norwegian biotech reaches the end of its cash runway.

Levicept arose from the metaphorical ashes of Pfizer’s former R&D campus in the U.K. Now, the biotech has scored a phase 2 win for an osteoarthritis drug that can also be traced back to the Big Pharma.

Three years since founding Site Alliance in 2021, Genentech is now sharing data showing sites in the alliance enroll more Black and Hispanic/Latinx patients than other sites in the same studies and enroll these underrepresented groups about two times faster.

After taking a look at phase 1 data, Nuvation Bio has decided to halt work on its one-time lead BD2-selective BET inhibitor while considering the program’s future.